Apyx Medical (NASDAQ:APYX) Releases Earnings Results, Beats Estimates By $0.01 EPS

Apyx Medical (NASDAQ:APYX) announced its earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, FiscalAI reports. The firm had revenue of $13.88 million for the quarter, compared to the consensus estimate of $13.18 million. Apyx Medical had a negative return on equity of 76.18% and a negative net margin of 14.78%.

Here are the key takeaways from Apyx Medical’s conference call:

• Second-quarter revenue rose 22% to $13.9 million, led by a 28% increase in surgical aesthetics sales to $12.4 million. Management attributed the growth to AYON adoption, higher international generator sales, and increased domestic single-use handpiece volume.
• AYON received FDA clearance for power-assisted liposuction, with initial shipments beginning in June and a broader commercial launch planned for the third quarter. Management said early surgeon feedback was “exceptional” and expects more than 95% of new AYON customers to include the PowerLipo attachment.
• Management highlighted clinical studies supporting Renuvion’s role in body contouring, including higher patient satisfaction and fewer abdominoplasty or revision procedures when combined with liposuction, while maintaining comparable complication rates.
• Profitability improved, with gross margin rising to 63.9%, operating loss narrowing to $1.8 million, and adjusted EBITDA loss improving to $0.7 million. However, operating cash use increased to $3.5 million, and the company ended the quarter with $27.6 million in cash.
• The company reaffirmed 2026 revenue guidance of $59 million to $60 million and expects OEM revenue to decline to approximately $5 million from $7.5 million in 2025. Tariffs are also pressuring margins, although potential tariff refunds are not included in current guidance.

Apyx Medical Stock Performance

Shares of APYX traded down $0.11 during mid-day trading on Friday, hitting $4.05. The stock had a trading volume of 299,178 shares, compared to its average volume of 64,993. The firm has a market cap of $169.74 million, a P/E ratio of -20.25 and a beta of 1.39. The business has a fifty day moving average price of $4.24 and a 200-day moving average price of $3.94. The company has a debt-to-equity ratio of 2.68, a current ratio of 5.80 and a quick ratio of 4.79. Apyx Medical has a 52 week low of $1.70 and a 52 week high of $5.08.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in APYX. Citadel Advisors LLC bought a new stake in Apyx Medical in the 3rd quarter valued at about $28,000. Osaic Holdings Inc. purchased a new position in shares of Apyx Medical in the second quarter worth about $50,000. Franklin Resources Inc. purchased a new position in shares of Apyx Medical in the third quarter worth about $59,000. Hudson Bay Capital Management LP bought a new stake in shares of Apyx Medical in the fourth quarter valued at approximately $73,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Apyx Medical in the fourth quarter valued at approximately $111,000. Institutional investors own 55.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on APYX. Zacks Research upgraded Apyx Medical to a “hold” rating in a report on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research note on Wednesday, June 24th. HC Wainwright initiated coverage on Apyx Medical in a research report on Monday, July 13th. They set a “buy” rating and a $7.00 target price for the company. Finally, Wall Street Zen cut Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.60.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.